Regulatory U.S. increasing distribution of monkey pox vaccine to contain...

U.S. increasing distribution of monkey pox vaccine to contain the spread

-

The U.S. government is sending thousands of vaccines to states in the following months in an effort to hamper the spread of monkeypox. This would improve the accessibility to the people who are more at risk of the disease as the government aims to increase the supply to localities with a higher number of cases.

According to the plan that was announced on Tuesday, there will be a quick expansion in access to the doses of the monkeypox vaccine from the Danish company Bavarian Nordic called Jynneos. Previously this vaccine has been limited, but to cater to the areas with high need, ample vaccines will be made available.

The vaccine is indicated for the prevention of monkeypox in people of age 18 and older.    

Emergent BioSolutions’ ACAM2000 vaccine will also be available on order by state or local health departments. This is in greater supply but only available on order due to the greater number of side effects. What also adds to its available-on-order status is that it cannot be used by people with compromised immune systems, making it not suitable for the mass public.

In the coming weeks, doses will be allocated by the Biden administration. From the national stockpile, 296,000 doses of Jyenneos will be allocated to the states and territories, of which 56,000 being immediate. According to officials, 1.6M doses will follow in the coming months.

306 cases of monkeypox exist in the United States. Monkeypox is an infection linked to smallpox, with the addition of painful skin abrasions. The virus is existent and widespread in parts of Africa. This is why the preventive measure is being taken elsewhere, to avoid widespread in other countries.

Dr. Rochelle Walensky, director at the Centers for Disease Control and Prevention, told reporters, “As additional supply becomes available, we will further expand our efforts, making vaccines available to a wider population.”

The existing strategy was focused on offering the vaccine to people who had had direct contact with anyone who was a confirmed case of monkeypox. According to Jennifer McQuistion, deputy director of CDC’s high consequence pathogens and pathology division, the new strategy will change that to include supposed exposures as well and not just confirmed cases. This means that the focus has shifted from the number of people actually exposed to those who are possibly or supposedly exposed, without confirmation.

The supposed exposures would include people who had close contact with anyone diagnosed with the disease, those who know that their sexual partner was diagnosed with the disease, and also men who have indulged in sexual activity with other men who have had multiple sexual partners recently in a locality where the disease is known to be spreading.

General idea is to take extreme precautions to avoid the widespread of the disease, which is why the slightest possibility of monkeypox exposure is being considered as an actual exposure and being treated as such.

According to the administration officials, the goal of this initial phase of the new strategy is to reduce the spread of monkeypox.

+ posts

Latest news

FDA and CDC exploring unlikely relation between COVID-19 vaccine and stroke

The FDA and CDC have brought out new revelations that the revised COVID-19 injection from Pfizer Inc...

Disappointing sales prompt AstraZeneca to pull out leukemia drug Lumoxiti from U.S. market

In a letter shared with healthcare providers, AstraZeneca has announced that it will be pulling its leukemia...

Sanofi’s Venture Capital units to receive over $750 million in investment to boost firm’s investment capabilities 

After a successful last year in which Sanofi Ventures made its second-highest number of deals, 10 rounds...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

Amgen’s KRAS drug gets early FDA approval for lung cancer with specific mutation

On Friday, the United States FDA (Food and Drug Administration) has authorized a medication of Amgen Biopharmaceutical in patients with NSCLC

You might also likeRELATED
Recommended to you